Skip to main content
TipRanks
Go Ultimate75% OFF

Braveheart Investment (TRUE) AI Stock Analysis

7 Followers
GB:TRUE

Braveheart Investment

(LSE:TRUE)

Select Model
Rating:40Underperform
Price Target:GBX 2.00â–¼(-11.11% Downside)
Action:downgraded
Date:10/21/26

The score is driven down primarily by weak financial performance—especially persistent cash burn and deteriorated/volatile operating results—despite low reported debt. Technicals add further pressure as the stock trades below all major moving averages with negative momentum. Valuation is not a clear positive because the negative P/E reflects ongoing losses and no dividend yield data is available.

Positive Factors
Minimal Financial LeverageMinimal debt reduces interest burden and refinancing exposure, giving Braveheart greater flexibility to manage its investment portfolio through difficult periods. Low leverage also leaves more room to deploy capital or support portfolio companies without the additional constraints created by substantial borrowings.
Negative Factors
Persistent Cash BurnPersistent negative operating cash flow indicates that the core business has not funded itself through operations. Continued cash consumption can force reliance on external funding or existing resources, limiting the capital available for investments and increasing pressure on future financial decisions.

Braveheart Investment (TRUE) vs. iShares MSCI United Kingdom ETF (EWC)

-40%-20%0%20%40%60%80%GB:TRUE+7.14%EWC+21.04%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 1.77M
Dividend Yield
―
Average Volume (3M)
80.26K
Price to Earnings (P/E)
-4.1
Beta (1Y)
0.31
Revenue Growth
―
EPS Growth
68.42%
Country
UK
Employees
3
Sector
Financial
Sector Strength
68
Industry
Asset Management

Braveheart Investment Business Overview & Revenue Model

Company Description

Truetide plc is a private equity and venture capital firm specializing in loan, mezzanine, seed/startup, early venture, late stage, emerging growth, turnaround, distress situations, buyout and growth capital companies. It prefers to invest in materia...

Braveheart Investment Financial Statement Overview

Summary

Overall fundamentals are weak. Income statement quality is poor (Score 18) with a sharp revenue collapse since 2021 and mostly loss-making operating results. Cash flow is a major risk (Score 14) with persistently negative operating cash flow and mostly negative free cash flow. The balance sheet is comparatively better (Score 62) due to minimal debt, but equity has eroded sharply, reflecting ongoing losses.

Income Statement

18Very Negative

Balance Sheet

62Positive

Cash Flow

14Very Negative
Financial statement breakdown
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue128.75K128.75K20.50K60.90K50.90K78.13K
Gross Profit60.32K60.32K-274.18K-366.56K-505.24K-558.01K
EBITDA-421.87K-421.87K-565.91K-811.88K-788.22K-695.49K
Net Income-424.97K-424.97K-1.09M-7.25M1.58M1.88M
Balance Sheet
Total Assets2.32M2.32M2.39M3.50M11.61M7.06M
Cash, Cash Equivalents and Short-Term Investments150.60K150.60K63.67K1.74M934.86K1.85M
Total Debt000000
Total Liabilities108.21K108.21K58.14K104.14K1.09M449.86K
Stockholders Equity2.22M2.22M2.33M3.40M10.52M6.63M
Cash Flow
Free Cash Flow-220.13K0-541.01K-736.12K-768.19K-1.28M
Operating Cash Flow-536.99K-536.99K-541.01K-736.12K-768.19K-1.27M
Investing Cash Flow344.32K344.32K-1.14M1.54M-1.08M-1.40M
Financing Cash Flow279.59K279.59K00930.36K2.42M

Braveheart Investment Technical Analysis

Technical Analysis SentimentNegative
Last Price2.25

Price Trends

50DMA2.78Negative
100DMA3.00Negative
200DMA2.70Negative

Market Momentum

MACD-0.16Negative
RSI1.95Positive
STOCH88.24Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:TRUE, the sentiment is Negative. The current price of 2.25 is below the 20-day moving average (MA) of 2.27, below the 50-day MA of 2.78, and below the 200-day MA of 2.70, indicating a bearish trend. The MACD of -0.16 indicates Negative momentum. The RSI at 1.95 is Positive, neither overbought nor oversold. The STOCH value of 88.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:TRUE.

Braveheart Investment Peers Comparison

Overall Rating

UnderperformOutperform
Sector (68)

Financial Indicators

GB:TRUE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *68Neutral$18.00B11.429.92%3.81%9.73%1.22%
GB:VOXGB:VOX52NeutralGBP 252.00K-5.18-13.43%―――
GB:BLUGB:BLU43NeutralGBP 2.30M-1.59-43.66%――83.53%
GB:PRIMGB:PRIM41NeutralGBP 3.54M2.6122.69%―――
GB:TRUEGB:TRUE40UnderperformGBP 1.77M-4.09-17.10%――68.42%
GB:GUNGB:GUN35UnderperformGBP 9.13M1.2522.42%―――

* Financial Sector Average

Performance Comparison

-50%0%50%GB:TRUEGB:BLUGB:GUNGB:PRIMGB:VOXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:TRUE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:TRUEBraveheart Investment2.250.157.14%
GB:BLUBlue Star Capital4.50-9.00-66.67%
GB:GUNGunsynd plc0.60-1.23-67.21%
GB:PRIMPrimorus Investments2.85-1.05-26.92%
GB:VOXVertu Capital0.170.000.00%

Braveheart Investment Corporate Events

Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance

Truetide corrects Paraytec update as VosBio lung cancer project completes Phase 2

Positive
Oct 20, 2026

Truetide said an earlier regulatory announcement had been corrected to clarify that its Paraytec-VosBio lung cancer project is using simulated air samples, not human breath, and to remove premature technical claims about particle characterisation and...

Business Operations and StrategyProduct-Related Announcements

Truetide’s Paraytec Advances Breath-Based Lung Cancer Detection Programme

Positive
Oct 15, 2026

Truetide plc has reported that Paraytec Limited, its wholly owned investee, has successfully completed Phase 2 of a six-month development programme with VosBio Inc. to combine VosBio’s breath-collection technology with Paraytec’s CX300 platform for e...

Business Operations and StrategyShareholder Meetings

Truetide Wins Shareholder Backing for New Investing Policy

Positive
Sep 7, 2026

Truetide plc has secured shareholder approval at a general meeting to amend its investing policy, with 83.79% of votes cast in favour of authorising the directors to implement the new strategy. The revised investing policy, which now takes immediate...

Business Operations and StrategyShareholder Meetings

Truetide Seeks Shareholder Backing for AI-Focused Expansion of Investing Strategy

Positive
Aug 21, 2026

Truetide plc has called a general meeting to seek shareholder approval for a significant expansion of its investing policy, adding a new artificial intelligence-focused strategy to its existing technology and knowledge-intensive investment framework....

Shareholder Meetings

Truetide Wins AGM Backing but Faces Pushback on Share Allotment Powers

Neutral
Jul 24, 2026

Truetide plc reported that all resolutions at its annual general meeting on 24 July 2026 were passed, including the reappointment of MAH Chartered Accountants as auditors and the re-election of directors Vivian Hallam, Trevor Brown and Qu Li. Voting...

Business Operations and StrategyShareholder Meetings

Truetide Plans AI-Focused Long-Short Investment Strategy Shift

Positive
Jul 24, 2026

Truetide has outlined plans at its Annual General Meeting to amend its investing policy to adopt a balanced long-short, AI-focused investment strategy. The approach will target companies seen as beneficiaries of artificial intelligence while taking s...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 21, 2026